Regulatory PathRegulatory requirements compared

Active substance

Methylene blue

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade nameStrengthForm · routePackPublic priceTypeCompanyStatus
METHYLENE BLUE 1%(50MG-5ML) AMP1 %Injection · Parenteral use5 AmpouleSAR 129.85Generic · PrescriptionHOSPIRA AUSTRALIAWithdrawn by MAH · Not Marketed

US FDA United States — FDA approvals (Drugs@FDA)

ProductStrengthForm · routeApplicantStatusFirst approved
PROVAYBLUE50MG/10ML (5MG/ML); 10MG/2ML (5MG/ML)solution · intravenousPROVEPHARM SASPrescription8 Apr 2016
METHYLENE BLUE10MG/2ML (5MG/ML); 50MG/10ML (5MG/ML); 5MG/ML (5MG/ML); 100MG/10ML (10MG/ML)solution · intravenousZYDUS LIFESCIENCESPrescription5 Dec 2023
METHYLENE BLUE50MG/10ML (5MG/ML)solution · intravenousNEXUSPrescription21 Nov 2024
METHYLENE BLUE50MG/10ML (5MG/ML)solution · intravenousSTERISCIENCEPrescription22 Nov 2024
METHYLENE BLUE50MG/10ML (5MG/ML)solution · intravenousHIKMA PHARMSPrescription17 Dec 2024
METHYLENE BLUE50MG/10ML (5MG/ML)solution · intravenousMEITHEALPrescription23 Jan 2025
METHYLENE BLUE50MG/10ML (5MG/ML)solution · intravenousXIROMEDPrescription30 Jul 2025
METHYLENE BLUE50MG/10ML (5MG/ML)solution · intravenousCHENGDU SHUODEPrescription23 Dec 2025

Canada Canada — marketed products (Health Canada)

BrandDINStrengthForm · routeCompany
METHYLENE BLEU LIQ 1%000504661 %LIQUID · ORALLABORATOIRE ATLAS INC
METHYLENE BLUE INJECTION0248799310 MG / MLSOLUTION · INTRAVENOUSPHEBRA PTY LTD
METHYLENE BLUE INJECTION USP0223077010 MG / MLLIQUID · INTRAVENOUSOMEGA LABORATORIES LIMITED

Safety signals and safety-related labeling changes

All safety entries for methylene blue →

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.